Publications by authors named "Aya Hefnawy"
Article Synopsis
- The study emphasizes the need for prospective drug resistance (DR) investigations in neglected tropical diseases (NTDs), particularly using Leishmania donovani and the drug TCMDC-143345 as examples.
- Researchers observed that it took longer for L. donovani to develop resistance to TCMDC-143345 compared to existing drugs, indicating a unique resistance mechanism without cross-resistance.
- Genetic analysis revealed two mutations in the LdoDLP1 protein that contribute to this resistance, affecting mitochondrial properties and suggesting a specific role of LdoDLP1 in the adaptation of L. donovani to the drug.
The growing drug resistance (DR) raises major concerns for the control of visceral leishmaniasis (VL), a neglected disease lethal in 95 percent of the cases if left untreated. Resistance has rendered antimonials (SSG) obsolete in the Indian Sub-Continent (ISC) and the first miltefosine-resistant Leishmania donovani were isolated. New chemotherapeutic options are needed and novel compounds are being identified by high-throughput screening (HTS).
View Article and Find Full Text PDFNew drugs are needed to control leishmaniasis and efforts are currently on-going to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field.
View Article and Find Full Text PDF